Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension

被引：0
|
作者：
Nazzareno Galiè
Sean Gaine
Richard Channick
J. Gerry Coghlan
Marius M. Hoeper
Irene M. Lang
Vallerie V. McLaughlin
Cheryl Lassen
Lewis J. Rubin
Shu-Fang Hsu Schmitz
Olivier Sitbon
Victor F. Tapson
Kelly M. Chin
机构：
[1] University of Bologna and IRCCS-S.Orsola University Hospital,Alma Mater Studiorum
[2] Mater Misericordiae University Hospital,David Geffen School of Medicine
[3] UCLA,undefined
[4] Royal Free Hospital,undefined
[5] Hannover Medical School and German Centre for Lung Research (DZL/BREATH),undefined
[6] Medical University of Vienna,undefined
[7] University of Michigan,undefined
[8] Actelion Pharmaceuticals Ltd,undefined
[9] University of California,undefined
[10] San Diego,undefined
[11] Hôpital Bicêtre,undefined
[12] Cedars-Sinai Medical Center,undefined
[13] University of Texas Southwestern Medical Center,undefined
[14] Université Paris-Sud,undefined
[15] INSERM Unité 999,undefined
来源：
Advances in Therapy | 2022年 / 39卷
关键词：
Selexipag; Pulmonary arterial hypertension; PAH; GRIPHON; Open-label extension; Safety; Tolerability; Survival; Combination therapy; Long-term outcomes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：796 / 810
页数：14
相关论文
共 50 条
  • [21] Effect of selexipag on long-term outcomes in patients with pulmonary arterial hypertension (PAH) receiving one, two or no PAH therapies at baseline: results from the GRIPHON study
    Lang, I.
    Gaine, S.
    Galie, N.
    Ghofrani, H. A.
    Le Brun, F. O.
    McLaughlin, V.
    Rubin, L. J.
    Simonneau, G.
    Sitbon, O.
    Hoeper, M.
    EUROPEAN HEART JOURNAL, 2015, 36 : 381 - 382
  • [22] Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension
    Richeldi, Luca
    Kreuter, Michael
    Selman, Moises
    Crestani, Bruno
    Kirsten, Anne-Marie
    Wuyts, Wim A.
    Xu, Zuojun
    Bernois, Katell
    Stowasser, Susanne
    Quaresma, Manuel
    Costabel, Ulrich
    THORAX, 2018, 73 (06) : 581 - 583
  • [23] Long-term safety of pirfenidone in RECAP, an open-label extension study in patients with idiopathic pulmonary fibrosis, interim results
    Costabel, Ulrich
    Albera, Carlo
    Fagan, Elizabeth
    Bradford, Williamson
    King, Talmadge
    Noble, Paul
    Sahn, Steven
    Valeyre, Dominique
    du Bois, Roland
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [24] Individualized Dosing of Selexipag Based on Tolerability in the GRIPHON Study Shows Consistent Efficacy and Safety in Patients With Pulmonary Arterial Hypertension (PAH)
    Channick, Richard
    Chin, Kelly
    Di Scala, Lilla
    Frey, Aline
    Preiss, Ralph
    Gaine, Sean
    Galie, Nazzareno
    Ghofrani, Hossein Ardeschir
    Hoeper, Marius
    Lang, Irene
    McLaughlin, Vallerie
    Rubin, Lewis
    Simonneau, Gerald
    Sitbon, Olivier
    Tapson, Victor
    CHEST, 2015, 148 (04)
  • [25] Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: An open-label extension trial
    McConville, B
    Carrero, L
    Sweitzer, D
    Potter, L
    Chaney, R
    Foster, K
    Sorter, M
    Friedman, L
    Browne, K
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2003, 13 (01) : 75 - 82
  • [26] LONG-TERM TOLERABILITY OF ZONISAMIDE IN PAEDIATRIC PATIENTS WITH EPILEPSY: RESULTS OF A PHASE II, OPEN-LABEL, EXTENSION STUDY
    Chouette, I.
    Giorgi, L.
    EPILEPSIA, 2012, 53 : 53 - 53
  • [27] Long-Term Safety, Tolerability and Efficacy of Macitentan in Patients with Inoperable Chronic Thromboembolic Pulmonary Hypertension: The MERIT-1 Study and Its Open-Label Extension MERIT-2
    Howard, L. S.
    Ghofrani, H. A.
    D'Armini, A. M.
    Fedullo, P.
    Gesang, S.
    Jais, X.
    Jenkins, D. P.
    Jing, Z.
    Madani, M. M.
    Mitchell, L.
    Mayer, E.
    Papadakis, K.
    Kim, N. H.
    Simonneau, G.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [28] Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial
    Ghofrani, Hossein-Ardeschir
    Grimminger, Friedrich
    Gruenig, Ekkehard
    Huang, Yigao
    Jansa, Pavel
    Jing, Zhi-Cheng
    Kilpatrick, David
    Langleben, David
    Rosenkranz, Stephan
    Menezes, Flavia
    Fritsch, Arno
    Nikkho, Sylvia
    Humbert, Marc
    LANCET RESPIRATORY MEDICINE, 2016, 4 (05): : 361 - 371
  • [29] Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: The TReprostinil sodium Inhalation Used in the Management of Pulmonary arterial Hypertension (TRIUMPH) study open-label extension
    Benza, Raymond L.
    Seeger, Werner
    McLaughlin, Vallerie V.
    Channick, Richard N.
    Voswinckel, Robert
    Tapson, Victor F.
    Robbins, Ivan M.
    Olschewski, Horst
    Rubin, Lewis J.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2011, 30 (12): : 1327 - 1333
  • [30] Long-Term Safety and Efficacy of Olokizumab in Patients with Rheumatoid Arthritis - Results of an Open-Label Extension Study
    Feist, Eugen
    Nasonov, Evgeny
    Luggen, Michael
    Fatenejad, Saeed
    Grishin, Sergey
    Samsonov, Mikhail
    Fleischmann, Roy
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 603 - 606
12345